Startups are sharpening AI-first models to accelerate biologics and clinical development. Latent Labs, formed by ex-DeepMind scientists, is marketing AI models that output drug-like biologics ready for development, while Formation Bio described an AI-native hub-and-spoke model to speed trials and cut development costs. Both companies emphasize asset-centric platform integration: Latent Labs focuses on one‑step biologic design for difficult targets, and Formation Bio combines licensed assets with internal execution engines for clinical planning, site operations and regulatory work. Formation disclosed large capital backing and an emphasis on clinical development as AI’s near-term leverage point. The two profiles illustrate growing investor appetite for companies that embed AI across discovery and development, but they also invite scrutiny on reproducibility, regulatory acceptance, and the ability to translate algorithmic outputs into human-grade therapeutics.